News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Niklas Klümper: Trastuzumab deruxtecan achieving high ORR in patients with advanced HER2-amplified solid tumors
globaloncologyacademy.org
Nov 11, 2024, 23:44

Niklas Klümper: Trastuzumab deruxtecan achieving high ORR in patients with advanced HER2-amplified solid tumors

Niklas Klümper, Senior Consultant for Urology and GU Oncology at University Hospital Bonn, shared a post on X:

“New data shows T-DXd achieving high ORR with durable response in patients with advanced HER2-amplified solid tumors, as determined by cfDNA testing!

A strong example of an elegant biomarker-based basket design, further supporting tumor-agnostic approval of T-DXd for HER2-positive cancers.”

Trastuzumab Deruxtecan in Advanced Solid Tumors With Human Epidermal Growth Factor Receptor 2 Amplification Identified by Plasma Cell-Free DNA Testing: A Multicenter, Single-Arm, Phase II Basket Trial.

Authors: Masataka Yagisawa, Hiroya Taniguchi, Taroh Satoh, Shigenori Kadowaki, Yu Sunakawa, Tomohiro Nishina, Yoshito Komatsu, Taito Esaki, Daisuke Sakai, Ayako Doi, Takeshi Kajiwara, Hiromi Ono, Masatoshi Asano, Nami Hirano, Justin Odegaard, Satoshi Fujii, Shogo Nomura, Hideaki Bando, Akihiro Sato, Takayuki Yoshino, Yoshiaki Nakamura

Niklas Klümper

Akihiro Sato Ayako Doi cancer cfDNA testing Daisuke Sakai HER2-positive cancers Hideaki Bando Hiromi Ono Hiroya Taniguchi Justin Odegaard Masataka Yagisawa Masatoshi Asano Nami Hirano Niklas Klümper OncoDaily Oncology Satoshi Fujii Shigenori Kadowaki Shogo Nomura solid tumors Taito Esaki Takayuki Yoshino Takeshi Kajiwara Taroh Satoh Tomohiro Nishina Trastuzumab deruxtecan Yoshiaki Nakamura Yoshito Komatsu Yu Sunakawa
Special Coverage
Blog
Nov 13, 2024, 09:55
Moderna Incorporation announced the awardees of its 2024 Australia Fellowship Program
Blog
Nov 13, 2024, 09:39
AI tools to improve diagnosis and therapy in neuro-oncology
Insight
Nov 13, 2024, 09:27
Nikki Rossetti et al. on Early-Stage Lung Cancer in the Era of Lung Cancer Screening
Blog
Nov 13, 2024, 09:14
Yüksel Ürün: Key takeaways on high-risk and locally advanced prostate cancer from António Rui Azevedo Freitas
Blog
Nov 13, 2024, 09:11
Clinical outcomes of early-stage triple-negative breast cancer after neoadjuvant chemotherapy
Blog
Nov 13, 2024, 09:09
Yüksel Ürün: Not all that shines is Prostate cancer – a striking reminder from Daniela Oprea-Lager
Blog
Nov 13, 2024, 09:01
Updated Results with Mitazalimab as a first-line treatment for advance pancreatic cancer
Blog
Nov 13, 2024, 08:59
Miriam Mutebi: What To Expect During A Mammogram
Insight
Nov 13, 2024, 08:56
Rachel Riechelmann: Low dose Everolimus for patients with Neuroendocrine tumors
Insight
Nov 13, 2024, 08:51
Reporting pharmacogenetic variants and cancer WGS data could guide safer prescribing
Blog
Nov 13, 2024, 08:49
Yüksel Ürün: Promising findings on SGLT2 as a biomarker for papillary RCC by Erman Akkus
Blog
Nov 13, 2024, 08:46
Karen Knudsen: Better Together - Partnering to Accelerate Progress against Cancer